SCHEMBL3105331

SCHEMBL3105331

O=C(O)Cc1ccc2cc[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.56
HPGD P15428 3/20 0.56
HSD17B10 Q99714 3/20 0.56
ALDH1A1 P00352 2/20 0.56
ENPP2 Q13822 2/20 0.56
NLRP3 Q96P20 3/20 0.55
MAPT P10636 2/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TYR P14679 1/20 0.48
PTGS1 P23219 1/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
RGS12 O14924 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29627552 1.00 KDM4E (0.56) KDM4EHPGDHSD17B10ALDH1A1ENPP2
Water SCHEMBL8810335 0.98 KDM4E (0.54) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL29518264 0.86 MAPT (0.56) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL3400912 0.86 MAPT (0.56) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL1607899 0.84 NLRP3 (0.53) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL30006017 0.84 NLRP3 (0.53) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL29820797 0.83 KDM4E (0.53) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL18132167 0.80 CYP1A2 (0.58) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL6675330 0.80 NLRP3 (0.64) KDM4EHPGDHSD17B10ALDH1A1ENPP2
SCHEMBL10645020 0.80 NLRP3 (0.60) KDM4EHPGDHSD17B10ALDH1A1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122081247-A Oncolytic vaccinia virus and recombinant viruses and methods of use thereof 2026-05-26 CN disclosed
US-12606557-B2 Substituted indoles with inhibitory activity UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2026-04-21 US disclosed
EP-4003977-B1 PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS TMEM16A LTD (GB) 2026-04-15 EP disclosed
US-12545658-B2 Pyridine derivatives as calcium-activated chloride channel modulators TMEM16A LIMITED (GB) 2026-02-10 US disclosed
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
CN-116554050-B Amide phenol derivative and application thereof 四川大学 2025-03-18 CN disclosed
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2025-01-14 US disclosed
EP-3573960-B1 N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES GENFIT (FR) 2023-08-16 EP disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
WO-1996003377-A1 HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS SANKYO COMPANY, LIMITED (JP) 1996-02-08 WO disclosed
US-5439906-A Antiarrhythmic benzodiazepines MERCK & CO., INC. (US) 1995-08-08 US disclosed
WO-1995014693-A1 IMIDAZOLINOBENZODIAZEPINES MERCK & CO., INC. (US) 1995-06-01 WO disclosed
WO-1995014472-A1 ANTIARRHYTHMIC BENZODIAZEPINES MERCK & CO., INC. (US) 1995-06-01 WO disclosed
EP-0290145-B1 Aliphatic carboxamides ICI AMERICA INC (US) 1994-10-26 EP disclosed
US-5288749-A Treating central nervous system or cardiovascular disorders ABBOTT LABORATORIES (US) 1994-02-22 US disclosed
WO-1993012754-A2 TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS ABBOTT LABORATORIES (US) 1993-07-08 WO disclosed
US-4894386-A ANTIINFLAMMATORY AGENTS ICI AMERICAS INC. (US) 1990-01-16 US disclosed
EP-0290145-A1 Aliphatic carboxamides ZENECA INC. (US) 1988-11-09 EP disclosed
US-4242120-A APPLYING A LOW MOLECULAR WEIGHT CARBOHYDRATE-CONTAINING MIXTURE TO A REPRODUCTIVE ZONE SIMFEROPOLSKY GOSUDARSTVENNY UNIVERSITET IMENI M.V. (SU) 1980-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT KDM4E 107/4885HPGD 4303/4885HSD17B10 3258/4885
US-12545658-B2 Pyridine derivatives as calcium-activated chloride channel modulators CACNA1E, CACNA1D, CACNA1B KDM4E 1939/4885HPGD 2613/4885HSD17B10 4107/4885
US-12606557-B2 Substituted indoles with inhibitory activity IDO1, BCL9, IDO2 KDM4E 1848/4885HPGD 1886/4885HSD17B10 570/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT KDM4E 107/4885HPGD 4303/4885HSD17B10 3258/4885
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT KDM4E 107/4885HPGD 4303/4885HSD17B10 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.